Old Web
English
Sign In
Acemap
>
authorDetail
>
John G. Bothos
John G. Bothos
AstraZeneca
Antibody-drug conjugate
Enzalutamide
Medicine
Programmed cell death
DNA
2
Papers
7
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I trial of MEDI3726, a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide.
2021
Clinical Cancer Research
Johann S. de Bono
Mark D. Fleming
Judy Sing-Zan Wang
Richard Cathomas
Manuel Selvi Miralles
John G. Bothos
Mary Jane Hinrichs
Qu Zhang
Peng He
Marna Williams
Anton I Rosenbaum
Meina Liang
Kapil Vashisht
Song Cho
Pablo Martinez
Daniel P. Petrylak
Show All
Source
Cite
Save
Citations (3)
MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.
2020
Journal of Clinical Oncology
Johann S. de Bono
Mark D. Fleming
Judy Sing-Zan Wang
Richard Cathomas
Marna Williams
John G. Bothos
Kemal Balic
Song Hye Cho
Pablo Martinez
Daniel P. Petrylak
Show All
Source
Cite
Save
Citations (4)
1